Development of 62Zn bleomycin as a possible PET tracer

Amir Reza Jalilian; Behrooz Fateh; Mitra Ghergherehchi; Alireza Karimian; Sedigheh Moradkhani; Mohsen Kamali-Dehghan; Faraj Tabeie

Development of ⁶²Zn bleomycin as a possible PET tracer

Amir Reza Jalilian
, Behrooz Fateh
, Mitra Ghergherehchi
, Alireza Karimian
, Sedigheh Moradkhani
, Mohsen Kamali-Dehghan
, Faraj Tabeie

Research output: Contribution to journal › Article › peer-review

Abstract

Bleomycin (BLM), labeled with radioisotopes, is widely used in therapy and diagnosis. In this study, BLM was labeled with ⁶²Zn for oncologic PET studies. The complex was obtained at pH = 2 in saline at 90°C in 25 min. Radio-TLC showed an overall radiochemical yield of 95-97% (radiochemical purity > 97%). Stability of complex was checked in vitro in mice and human plasma/urine. Preliminary in vivo studies were performed to determine complex stability and distribution of ⁶²Zn BLM in normal and fibrosarcoma-bearing mice. ⁶²Zn BLM accumulated significantly in induced fibrosarcoma tumors in mice according to biodistribution/imaging studies. ⁶²Zn BLM can be used in PET oncology studies due to its suitable physicochemical properties as a diagnostic complex in vitro and in vivo. Further studies should be performed for evaluation of the complex behavior in larger mammals.

Original language	English
Pages (from-to)	143-148
Number of pages	6
Journal	Nukleonika
Volume	50
Issue number	4
State	Published - 2005
Externally published	Yes

Keywords

Zn
Biodistribution
Bleomycin
PET
Pharmacokinetics

Cite this

@article{e5eaf730f2b946a185d357023be47dfa,

title = "Development of 62Zn bleomycin as a possible PET tracer",

abstract = "Bleomycin (BLM), labeled with radioisotopes, is widely used in therapy and diagnosis. In this study, BLM was labeled with 62Zn for oncologic PET studies. The complex was obtained at pH = 2 in saline at 90°C in 25 min. Radio-TLC showed an overall radiochemical yield of 95-97\% (radiochemical purity > 97\%). Stability of complex was checked in vitro in mice and human plasma/urine. Preliminary in vivo studies were performed to determine complex stability and distribution of 62Zn BLM in normal and fibrosarcoma-bearing mice. 62Zn BLM accumulated significantly in induced fibrosarcoma tumors in mice according to biodistribution/imaging studies. 62Zn BLM can be used in PET oncology studies due to its suitable physicochemical properties as a diagnostic complex in vitro and in vivo. Further studies should be performed for evaluation of the complex behavior in larger mammals.",

keywords = "Zn, Biodistribution, Bleomycin, PET, Pharmacokinetics",

author = "Jalilian, \{Amir Reza\} and Behrooz Fateh and Mitra Ghergherehchi and Alireza Karimian and Sedigheh Moradkhani and Mohsen Kamali-Dehghan and Faraj Tabeie",

year = "2005",

language = "English",

volume = "50",

pages = "143--148",

journal = "Nukleonika",

issn = "0029-5922",

publisher = "Institute of Nuclear Chemistry and Technology",

number = "4",

}

TY - JOUR

T1 - Development of 62Zn bleomycin as a possible PET tracer

AU - Jalilian, Amir Reza

AU - Fateh, Behrooz

AU - Ghergherehchi, Mitra

AU - Karimian, Alireza

AU - Moradkhani, Sedigheh

AU - Kamali-Dehghan, Mohsen

AU - Tabeie, Faraj

PY - 2005

Y1 - 2005

N2 - Bleomycin (BLM), labeled with radioisotopes, is widely used in therapy and diagnosis. In this study, BLM was labeled with 62Zn for oncologic PET studies. The complex was obtained at pH = 2 in saline at 90°C in 25 min. Radio-TLC showed an overall radiochemical yield of 95-97% (radiochemical purity > 97%). Stability of complex was checked in vitro in mice and human plasma/urine. Preliminary in vivo studies were performed to determine complex stability and distribution of 62Zn BLM in normal and fibrosarcoma-bearing mice. 62Zn BLM accumulated significantly in induced fibrosarcoma tumors in mice according to biodistribution/imaging studies. 62Zn BLM can be used in PET oncology studies due to its suitable physicochemical properties as a diagnostic complex in vitro and in vivo. Further studies should be performed for evaluation of the complex behavior in larger mammals.

AB - Bleomycin (BLM), labeled with radioisotopes, is widely used in therapy and diagnosis. In this study, BLM was labeled with 62Zn for oncologic PET studies. The complex was obtained at pH = 2 in saline at 90°C in 25 min. Radio-TLC showed an overall radiochemical yield of 95-97% (radiochemical purity > 97%). Stability of complex was checked in vitro in mice and human plasma/urine. Preliminary in vivo studies were performed to determine complex stability and distribution of 62Zn BLM in normal and fibrosarcoma-bearing mice. 62Zn BLM accumulated significantly in induced fibrosarcoma tumors in mice according to biodistribution/imaging studies. 62Zn BLM can be used in PET oncology studies due to its suitable physicochemical properties as a diagnostic complex in vitro and in vivo. Further studies should be performed for evaluation of the complex behavior in larger mammals.

KW - Zn

KW - Biodistribution

KW - Bleomycin

KW - PET

KW - Pharmacokinetics

UR - https://www.scopus.com/pages/publications/30744442338

M3 - Article

AN - SCOPUS:30744442338

SN - 0029-5922

VL - 50

SP - 143

EP - 148

JO - Nukleonika

JF - Nukleonika

IS - 4

ER -

Development of ⁶²Zn bleomycin as a possible PET tracer

Abstract

Keywords

Other files and links

Fingerprint

Cite this